A combination of an enzyme called serratiopeptidase and a natural fat called palmitoleic acid significantly improved PCOS symptoms in rats, according to a 2026 animal study. The combination treatment reduced ovarian cysts, improved hormone imbalances, and enhanced blood sugar control more effectively than either treatment alone. However, Gram Research analysis notes this is early-stage research in animals only—human clinical trials are needed before this approach could become a medical treatment.
Researchers tested a new combination treatment for polycystic ovary syndrome (PCOS), a common hormonal condition affecting many women. They combined two substances—an enzyme called serratiopeptidase packaged in tiny particles, plus a natural fat called palmitoleic acid—and tested it in rats with PCOS. According to Gram Research analysis, the combination worked better than either treatment alone, improving hormone levels, blood sugar control, and ovary health. While these early results are encouraging, the treatment has only been tested in animals so far, and human studies are needed before doctors could recommend it to patients.
Key Statistics
A 2026 animal study of 30 rats found that combining niosomal serratiopeptidase with palmitoleic acid reduced ovarian volume and improved hormone levels significantly more than either treatment alone in rats with PCOS.
In the 2026 study, serratiopeptidase was successfully encapsulated in niosomal particles at 74% efficiency, with an average particle size of 747 nanometers, demonstrating effective formulation of the experimental treatment.
Rats receiving the combination treatment showed improvements in fasting blood glucose, insulin levels, and HOMA-IR (insulin resistance marker) that approached normal levels, compared to partial improvements with single treatments.
The 2026 research found that while serratiopeptidase niosomes or palmitoleic acid alone produced some improvements in PCOS parameters, the combination produced the greatest effects across metabolic, hormonal, and ovarian measures.
The Quick Take
- What they studied: Whether combining an enzyme called serratiopeptidase with a natural fat called palmitoleic acid could help treat PCOS, a condition where women’s ovaries develop cysts and hormone levels become imbalanced.
- Who participated: The study used 30 young female rats divided into six groups. Some rats were healthy controls, while others were given PCOS using a drug and high-fat diet to mimic the human condition.
- Key finding: Rats receiving both the enzyme treatment and palmitoleic acid together showed the biggest improvements in ovary health, hormone balance, and blood sugar control compared to rats getting either treatment alone.
- What it means for you: This is early-stage research in animals only. While the results are promising, human clinical trials are needed before this combination could become a treatment option. Women with PCOS should continue working with their doctors on proven treatments.
The Research Details
Researchers created a rat model of PCOS by giving young female rats a drug called letrozole combined with a high-fat diet for 30 days. This mimics how PCOS develops in humans. They then divided the rats into six groups: healthy controls, untreated PCOS rats, and four groups receiving different treatments for 30 days.
The main treatment being tested was serratiopeptidase, an enzyme that breaks down proteins and reduces inflammation. The researchers packaged this enzyme into tiny particles called niosomes (about 750 nanometers in size) to help it work better in the body. They tested this niosomal serratiopeptidase alone, palmitoleic acid (a healthy fat) alone, and the combination of both.
After treatment, the researchers measured multiple markers of PCOS: ovary size and weight, number of ovarian cysts, hormone levels (testosterone, luteinizing hormone, follicle-stimulating hormone), blood sugar levels, and insulin resistance. They also examined ovary tissue under a microscope to see structural changes.
This study design is important because it tests a combination approach rather than single treatments. PCOS is a complex condition involving inflammation, hormone imbalance, and metabolic problems, so combination treatments may work better than single therapies. Using niosomes to package the enzyme is also significant because it helps the enzyme survive in the body longer and reach target tissues more effectively.
This is a preclinical animal study, which is an early stage of research. The sample size is small (30 rats total, 5 per group), which limits how much we can generalize the findings. The study was well-designed with proper controls and measured multiple relevant outcomes. However, animal studies don’t always translate to human results due to biological differences. The researchers were transparent about these limitations and emphasized that human clinical trials are needed.
What the Results Show
Rats with PCOS that received the combination of niosomal serratiopeptidase plus palmitoleic acid showed the most dramatic improvements. Their ovary volumes decreased significantly, ovarian cysts reduced in number, and hormone levels moved closer to normal. Specifically, testosterone levels (which are abnormally high in PCOS) decreased substantially, while follicle-stimulating hormone (which is abnormally low) increased toward normal ranges.
Blood sugar control also improved markedly in the combination treatment group. Fasting blood glucose levels, fasting insulin levels, and HOMA-IR (a measure of insulin resistance) all improved significantly with the combination treatment. These metabolic improvements are important because insulin resistance is a major driver of PCOS symptoms.
When either treatment was used alone—serratiopeptidase niosomes by themselves or palmitoleic acid by itself—there were partial improvements in some measures. However, these single treatments did not produce the same magnitude of benefit as the combination. Some improvements with single treatments didn’t reach statistical significance, meaning they could have occurred by chance.
The niosomes themselves were well-designed, with an average particle size of about 747 nanometers and successful encapsulation of 74% of the serratiopeptidase enzyme, indicating good formulation quality.
The study also found that PCOS rats had irregular estrous cycles (the animal equivalent of menstrual cycles), which improved with treatment, particularly with the combination approach. Ovarian weight relative to body weight (the ovarian index) was significantly elevated in PCOS rats and decreased with combination treatment. Histological examination of ovary tissue showed structural improvements with the combination treatment, with better-preserved follicle architecture and reduced fibrosis.
This research builds on existing knowledge that serratiopeptidase has anti-inflammatory properties and that palmitoleic acid (an omega-7 fatty acid) may improve insulin sensitivity. Previous studies have suggested both compounds individually might help with PCOS symptoms, but this appears to be the first study testing them together in a niosomal formulation. The combination approach aligns with current thinking that PCOS requires multi-targeted treatment addressing inflammation, hormone balance, and metabolic dysfunction simultaneously.
This study has several important limitations. First, it was conducted only in rats, not humans, so results may not translate directly to people. Second, the sample size was small (only 5 rats per group), which limits statistical power. Third, the study duration was relatively short (30 days of treatment), so we don’t know about long-term effects or safety. Fourth, the niosomal formulation is experimental and not yet available as a medical treatment. Finally, the study doesn’t explain the exact biological mechanisms by which the combination works, making it harder to predict how it might perform in humans.
The Bottom Line
Based on this preclinical research, no clinical recommendations can be made yet. This is early-stage research that must be followed by human clinical trials before any treatment could be recommended. Women with PCOS should continue working with their healthcare providers on evidence-based treatments including lifestyle modifications, medications like metformin, and hormonal contraceptives as appropriate. Moderate confidence: This finding is promising but requires human validation.
Women with PCOS or those interested in PCOS research should find this encouraging as a potential future treatment direction. Researchers studying PCOS, inflammation, and metabolic disorders should pay attention to this combination approach. However, this research is not yet ready for clinical application, so it shouldn’t influence current treatment decisions.
Since this is animal research, there is no timeline for human application yet. Typically, promising preclinical findings require 5-10 years of additional research (laboratory studies, safety testing, and human clinical trials) before becoming available as a treatment. Realistic expectations: This is a ‘watch this space’ finding, not something available now.
Frequently Asked Questions
Can I take serratiopeptidase and palmitoleic acid now to treat my PCOS?
Not based on this research. This study was conducted only in rats using an experimental niosomal formulation not available as a medical product. Human clinical trials are required before any recommendation could be made. Consult your doctor about proven PCOS treatments.
How does serratiopeptidase help with PCOS symptoms?
Serratiopeptidase is an enzyme that breaks down proteins and reduces inflammation. Since PCOS involves chronic inflammation and hormonal imbalance, reducing inflammation may help restore normal ovary function and hormone balance, though the exact mechanisms require further study.
What is palmitoleic acid and why might it help PCOS?
Palmitoleic acid is an omega-7 fatty acid found naturally in some foods like macadamia nuts and sea buckthorn. Research suggests it may improve insulin sensitivity and reduce inflammation, both of which are problematic in PCOS, making it a logical candidate for combination therapy.
When will this treatment be available for humans with PCOS?
This is unknown. The research is in early preclinical stages. If human clinical trials begin soon, it typically takes 5-10 years of additional research before a new treatment could become available. Continue working with your doctor on current evidence-based PCOS treatments.
Why did the combination treatment work better than single treatments?
PCOS involves multiple problems: inflammation, hormone imbalance, and insulin resistance. The combination approach targets multiple issues simultaneously—serratiopeptidase addresses inflammation while palmitoleic acid improves insulin sensitivity—which may explain superior results compared to single treatments.
Want to Apply This Research?
- Track PCOS-related symptoms weekly: menstrual cycle regularity (cycle length and consistency), energy levels (1-10 scale), bloating severity (1-10 scale), and hair growth changes. This baseline tracking will be valuable if and when human trials begin, allowing women to monitor whether future treatments show similar benefits to those seen in this animal study.
- While waiting for potential future treatments, use the app to implement proven PCOS management strategies: track daily physical activity (aim for 150 minutes weekly), log meals to monitor carbohydrate quality and portion sizes, and record sleep duration (target 7-9 hours). These evidence-based lifestyle changes address the same metabolic and hormonal issues this combination treatment targets.
- Set up monthly check-ins to review trends in hormone-related symptoms (irregular periods, acne, hair growth), metabolic markers (energy crashes, weight changes), and inflammatory symptoms (joint pain, general inflammation). As this research progresses toward human trials, this historical data could help you participate in future clinical studies or discuss emerging treatments with your doctor.
This article discusses early-stage animal research and should not be interpreted as medical advice or a treatment recommendation. The findings are from a preclinical rat study and have not been tested in humans. Women with PCOS should continue working with their healthcare providers on evidence-based treatments including lifestyle modifications, medications, and hormonal therapies as appropriate. Do not start, stop, or change any PCOS treatment based on this research. Consult your doctor before taking any supplements or considering experimental treatments. This research is promising but requires human clinical trials before any clinical application.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.